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Introduction
Second-trimester Down syndrome (DS) serum screening
by maternal age and measurement of α-fetoprotein
(AFP) and human chorionic gonadotropin (hCG) has
been an established practice in Taiwan since 1994 [1,2].
The average detection rate of this screening double test
is around 56%, with a 4.9% false-positive rate, which is
compatible to that of Western countries [3]. The dou-
ble test has had a huge impact in Taiwan, dramatically
decreasing live births of children with DS during the last
decade [4].
Only one tertiary center in Taiwan studied uncon-
jugated estriol (uE3), in addition to hCG and AFP, as
the third marker (triple test). Patient blood samples were
stored in 1996 and uE3 levels analyzed in 2000. The
overall DS detection rate of the triple test was as high as
78.6% [5]. Inhibin A is a heterodimeric glycoprotein
mainly secreted from the corpus luteum and the placenta
[6,7]. Previous studies have shown that second-trimester
serum inhibin levels are raised in the serum of pregnant
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SUMMARY
Objective: To assess the usefulness of quadruple test screening for Down syndrome in Taiwan.
Materials and Methods: Maternal serum concentrations of α-fetoprotein, human chorionic gonadotropin,
unconjugated estriol, and inhibin A were measured in 21,481 pregnant women from 15 to 20 weeks of gestation.
Results: Of the 21,481 women, 977 returned values greater than the high-risk cut-off value (1 in 270). Most 
of these women (86.2%) decided to have an invasive procedure for genetic diagnosis. Nine cases of Down 
syndrome and 19 cases of other chromosomal anomalies were detected prenatally. Two children with Down
syndrome were diagnosed after delivery even though a low estimated risk was determined following the quadru-
ple test. The detection rate was 81.8% (nine out of 11 cases), with a 4.4% false-positive rate. The median multiple
of the median value for α-fetoprotein, human chorionic gonadotropin, unconjugated estriol and inhibin A were
0.87, 2.34, 0.77 and 2.16, respectively, in affected cases.
Conclusion: This is the first study of the quadruple test for Down syndrome in a Chinese population. Our findings
suggested that the second-trimester quadruple test provides an effective screening tool for Down syndrome in
Taiwan. [Taiwan J Obstet Gynecol 2010;49(1):30–34]
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women carrying a fetus with DS [8,9]. Thus, the incor-
poration of inhibin A into maternal serum DS screening
in the second trimester, along with AFP, hCG and uE3,
was named the quadruple test, and was first used in
1996 [10]. The detection rate of the quadruple test is
approximately 83%, which is comparable with the first-
trimester combined test (nuchal translucency, β-hCG
and pregnancy associated plasma protein A) [11].
According to the guidelines published by the
American College of Obstetrics and Gynecologists,
triple or quadruple testing should be offered to preg-
nant women when certificated doctors are not avail-
able to perform a first-trimester combined test [12].
The quadruple test began to be provided to the gen-
eral population in Taiwan in January of 2008 [3]. The
standard reference range for inhibin A has never been
determined among Asian women, so a pilot study to
determine normal values was performed for the pur-
pose of establishing a database.
This is the first study describing the efficiency of
using four DS markers for screening of a Chinese pop-
ulation. We evaluated the second-trimester quadruple
test for DS in terms of simplicity, feasibility, and relia-
bility among Taiwanese pregnant women.
Materials and Methods
From July to December 2008, we conducted a popula-
tion-based study of a second-trimester DS screening
program. All of the women enrolled in the study were in
their 15th to 20th week of gestation. These women were
offered routine prenatal examinations in local hospitals
or clinics where neither certified sonographers nor doc-
tors were available to perform first-trimester nuchal
translucency scanning. Since first-trimester combined
testing was not possible, maternal serum testing was rec-
ommended and performed by local doctors. Only sin-
gleton and healthy pregnancies were enrolled in the
study. The exclusion criteria included multiple pregnan-
cies, maternal diabetes or cardiac disease, illiteracy
(inability to read and sign the consent forms), and
known high-risk pregnancies originally referred from the
medical center. Ten milliliters of blood were taken from
each eligible subject for study.
All basic pregnancy data, including age, body weight,
delivery history, smoking history, assisted reproductive
technologies used and ethnicity, were recorded. Every
sample was collected and sent to a central laboratory
in order to decrease the inter-operator error. The mul-
tiple of the medians (MoMs) for hCG, uE3, AFP and
inhibin A were analyzed using the Access chemilumi-
nescent enzyme-linked immunoassay system (Beckman
Coulter, Inc., Brea, CA, USA) with a built-in calibration
system. The testing was performed according to the
manufacturer’s instructions.
Risk calculation was performed using Benetech pre-
natal risk assessment software (Benetech Inc., Toronto,
ON, Canada). Maternal age, body weight, ethnicity, cig-
arette smoking and the level of the four markers were
factored in by the software. The high-risk cut-off level
was defined as a risk greater than 1 in 270. Once high-risk
women were identified, they were informed immedi-
ately via telephone either by their doctors or by well-
trained nurses. The women were then given a counseling
session regarding further invasive genetic testing, such as
amniocentesis. High-risk patients could decide either to
have amniocentesis at the local hospital or to receive 
a referral to a medical center. The final results of this
examination were recorded in the central laboratory.
Women at low risk for DS who had amniocentesis for
any reason or live-born DS babies were also recorded.
Statistical analyses were performed using SPSS 
version 12.0 (SPSS Inc., Chicago, IL, USA) computer
software. All the variables were checked for normal dis-
tributions using normal probability plots. Correlation
between variables was computed using Pearson’s cor-
relation test. Differences between the normal population
and affected fetuses were determined using the Mann-
Whitney U test. Statistical significance was defined at
p < 0.05.
Results
There were 102,944 babies born from July to December
2008 in Taiwan. After exclusion of unsuitable sub-
jects, 21,481 pregnant women were enrolled into this 
population-based study. The coverage rate was as high
as 20.87%, meaning that over one-fifth of pregnant
women underwent the second-trimester quadruple test.
Mean maternal age and maternal body weight were
29.5 ± 3.6 years and 57.3 ± 8.1 kg, respectively.
The standard curves of inhibin A, hCG, AFP and
uE3 were created from 372 normal pregnant women
at 15 to 20 weeks gestation at the National Taiwan
University Hospital. Log linear regression was applied
to AFP and uE3. Exponential and log quadratic re-
gression were used for hCG and inhibin A, respectively
(Figure). Table 1 shows the distributions of the four
serum markers by gestational week. The regression
medians used to calculate MoMs of AFP, hCG, uE3
and inhibin A for each gestational age were generated
from individual formulas provided by assay manufac-
turer. Thus, we uploaded our own Chinese data into
the risk calculation software.
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The quadruple test revealed 977 high-risk pregnan-
cies, with cut-off levels greater than 1 in 270. Of these
977 high-risk pregnancies, 840 women (86%) decided to
have an invasive procedure for a genetic diagnosis.
According to the reporting system, 28 chromosomal
anomalies were detected, including nine DS, six sex
chromosomal abnormalities, four unbalanced translo-
cations, five cases of trisomy 18, and four cases of tri-
somy 13. During the 6-month study period, local
doctors reported two children were born with DS, and
that the initial risk assessments of DS indicated low risk
in both cases. The detection rate was 81.8% (9/11)
with a 4.4% false-positive rate.
Table 2 shows mean maternal age, body weight, ges-
tational age and average MoM for each DS marker.
Cases 1 to 9 were affected fetuses that were diagnosed
prenatally by high-risk screening. All nine pregnancies
were terminated. The MoMs of affected fetuses for AFP,
hCG, uE3 and inhibin-A were 0.87, 2.34, 0.77 and 2.16,
respectively. The differences in the MoM between the
normal population and the affected population differed
significantly (p < 0.05) for each serum marker. There was
no difference in maternal age or maternal body weight
(Table 3). Patients of Case 10 and 11 were born with DS
despite low-risk results for the four-marker screening
test. The overall risks for DS of these two cases were
extremely low, without any ultra-high or ultra-low values
for any single marker (Table 2).
Discussion
We report the results of second-trimester quadruple
screening for DS in a Chinese population. Since there
was no available data for inhibin A among Asian women,
we also established reference values for this marker and
a calculation system to use before clinical testing. Our
regression curves for the four markers were normally dis-
tributed. The most difficult part of the quadruple test
was testing for inhibin A, as the regression line needed
Table 1. Regression of the four markers in weeks 15–20 of gestation
Week n
AFP (ng/mL) hCG (mIU/mL) uE3 (ng/mL) Inhibin A (pg/mL)
Observed Regressed Observed Regressed Observed Regressed Observed Regressed
15 24 36.24 31.35 42,814 38,163 0.6404 0.69 242.30 212.62
16 87 43.01 37.79 32,064 30,921 0.8489 0.86 218.94 182.65
17 96 44.89 45.54 32,641 26,237 1.0310 1.08 190.44 168.66
18 104 56.75 54.88 25,496 23,206 1.2995 1.35 198.39 167.41
19 51 71.63 66.14 23,297 21,245 1.5546 1.69 198.30 178.62
20 10 97.93 79.71 20,450 19,977 2.4862 2.11 227.85 204.86
AFP =a-fetoprotein; hCG = human chorionic gonadotropin; uE3 = unconjugated estriol.
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Figure. Standard curves of inhibin A, human chorionic gonadotropin (hCG), α-fetoprotein (AFP) and unconjugated estriol
(uE3) were created from 372 normal pregnant women at 15–20 weeks’ gestation attending the obstetrics department at the
National Taiwan University Hospital. Log linear regression was applied to AFP and uE3. Exponential and log quadratic regres-
sion were used for human chorionic gonadotropin and inhibin A, respectively.
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more cases in the 15 or 20 weeks gestational age range
to be complete. Our detection rate was 81.8%, which is
comparable to most of the quadruple test studies in the
world [13–16]. The false-positive rate was just under
5%, which led to fewer unnecessary invasive procedures
than other screening strategies.
Only 11 DS cases were found among the 21,481
enrolled pregnancies, which was much lower than the
incidence rate. This is mostly because all participants
were recruited from local hospitals and clinics, not
medical centers. When first-trimester combined test-
ing was provided, couples usually elected early invasive
genetic testing. When chromosomal anomalies were
detected, these pregnancies were usually terminated at
the parents’ requests. Furthermore, for the pregnant
population with advanced maternal age in Taiwan
(older than 34 years), amniocentesis was accepted
directly without any DS screening [17].
The screening strategy and clinical guidelines out-
lined by the Taiwan Society of Perinatology recommend
the first-trimester combined test as the method of choice
[3]. There are only 40 to 50 qualified and certified
obstetricians in Taiwan, which is far too few to meet the
current demand. Quadruple maternal serum testing is
fast becoming the second test of choice for DS screening
in the United States and United Kingdom [12]. Because
nuchal translucency scanning is not available in local
hospitals, a reliable, easy, simple blood test is the best
test methodology for both patients and doctors.
One of the limitations of this study was that report-
ing of high-risk pregnancies from local hospitals to the
central laboratory was only 85.5% (data not shown).
A comprehensive network needs to be established so
that every woman who undergoes amniocentesis can be
monitored. Secondly, the number of detected DS cases
was small. Since a large population of pregnant women
carrying fetuses with DS were detected early in their
first trimester using the combined test in medical cen-
ters, obtaining blood samples from those mothers at 15
to 20 weeks gestation for positive controls would be
highly beneficial to our study and the creation of data-
base values. Finally, the data we collected was mostly
from younger women. If the reference and testing sam-
ples incorporated data from older women, the findings
may be much more convincing.
In conclusion, our preliminary study demonstrates
DS detection rates with ideal false-positive rates in a
Chinese population using the second-trimester quadru-
ple test, comparable to that seen in Western countries.
This test for DS screening in the Chinese population
could be applied to routine prenatal checkups, especially
when the clinical service is unable to provide certified
and qualified ultrasonography personnel. A larger study
with an older population is needed to determine cut-off
values for that specific population.
Table 2. Down syndrome cases
Case
GA Mat age Weight AFP hCG uE3 Inhibin-A Estimated 
Outcome
(wk) (yr) (kg) (MoM) (MoM) (MoM) (MoM) risk
1 17 25.5 91.6 0.55 2.34 0.59 2.54 1:6 Terminated
2 18 31.3 57.1 0.64 1.5 0.76 1.39 1:28 Terminated
3 15 27.0 53.2 1.27 2.46 0.71 5.48 1:60 Terminated
4 16 30.5 60.1 0.67 1.65 0.63 1.33 1:68 Terminated
5 16 34.0 66.3 0.73 4.24 1.07 2.50 1:39 Terminated
6 17 29.1 52.9 0.67 1.66 0.79 2.11 1:64 Terminated
7 16 29.4 51.6 1.31 3.00 0.63 1.26 1:197 Terminated
8 19 30.1 53.3 0.66 1.41 0.35 1.59 1:109 Terminated
9 18 35.2 48.2 0.65 4.86 0.77 3.13 1:6 Terminated
10 15 21.7 41.3 1.34 1.62 1.04 1.57 1:4,190 Live born
11 17 29.0 64.4 1.07 1.05 1.12 0.89 1:38,500 Live born
Mean 16.7 29.35 58.18 0.87 2.34 0.77 2.16
GA = gestational age; Mat = maternal; AFP = a-fetoprotein; MoM = multiple of the median; hCG = human chorionic gonadotropin; uE3 = unconjugated estriol.
Table 3. Comparison of unaffected and affected groups
Unaffected Affected p
No. of sample 21,470 11
Maternal age, 29.5 29.35 NS
mean (yr)
Maternal weight, 57.29 58.18 NS
mean (kg)
AFP (MoM) 1.05 0.87 < 0.05
hCG (MoM) 0.97 2.34 < 0.05
uE3 (MoM) 1 0.77 < 0.05
Inhibin A (MoM) 1.04 2.16 < 0.05
AFP = a-fetoprotein; MoM = multiple of the median; hCG = human chorionic
gonadotropin; uE3 = unconjugated estriol; NS = not significant.
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